AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: completion of questionnaires
Description: igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of questionnaires
Description: igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
Study NCT04143282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus chemotherapy
Description: determine the effect of metformin along with standard chemotherapy
Study NCT04143282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: standard chemotherapy
Study NCT04172025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of Bacterial Genome
Description: genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
Study NCT00758563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush twice daily
Study NCT01990690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti oxidant omega 3
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
Study NCT01990690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti oxidant omega 3
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + bevacizumab
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + everolimus (RAD001)
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: completion of questionnaires for pain
Description: analogical visual and numerical scale and Borg scale
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of questionnaires for pain
Description: analogical visual and numerical scale and Borg scale
Study NCT00678795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours
Study NCT00678795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
Study NCT03724370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Monitoring System
Description: TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
Study NCT03724370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VHA-SRM
Description: Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
Study NCT03724370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VHA-SRM
Description: Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
Study NCT03203798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training of pelvic floor muscles
Description: The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
Study NCT03203798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hipopressive abdominal gymnastics
Description: The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
Study NCT04107805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet
Study NCT04107805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT04107805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration
Study NCT00768131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
Study NCT00768131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
Study NCT00768131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
Study NCT00768131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
Study NCT00768131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
Study NCT03960983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with tongue scraper
Description: Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
Study NCT03960983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hygiene procedures for the mucosa and dentures
Description: Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
Study NCT03960983 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
Study NCT03960983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene procedures for the mucosa and dentures
Description: Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
Study NCT03260205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
Study NCT03260205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
Study NCT03260205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: SPD489
Study NCT04008589 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transorbital AC Stimulation
Description: Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
Study NCT04008589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transorbital AC Stimulation
Description: Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
Study NCT04008589 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: combination of transcranial direct current stimulaton and rtACS
Description: Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
Study NCT04008589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination of transcranial direct current stimulaton and rtACS
Description: Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
Study NCT01532323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taking of saliva before and after gustatory stimulation
Description: Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
Study NCT01532323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking of saliva before and after gustatory stimulation
Description: Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
Study NCT01443455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: videodance
Description: Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
Study NCT01443455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk Walking
Description: The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
Study NCT01443455 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: delayed entry control
Description: Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------
Study NCT04867655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange Juice
Description: Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
Study NCT04867655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice with either 6g or 3 g of β-Glucan
Description: Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
Study NCT01592279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Study NCT01592279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin injections
Study NCT02084368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
Study NCT02084368 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Combined spinal and epidural anesthesia
Description: Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
Study NCT02869958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital action plan for asthma exacerbations + Written action plan
Description: Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
Study NCT02869958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written action plan
Study NCT01051583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Description: The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
Study NCT02084368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
Study NCT02084368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
Study NCT04991012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Therapy
Description: the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
Study NCT01051583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Description: The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
Study NCT02286999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. infantis
Description: Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
Study NCT02286999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04991012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Substance) therapy side
Description: th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
Study NCT01008137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (PANFLU.1)
Description: H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Study NCT02777632 — intervention group
Intervention type: PROCEDURE
Intervention: Living donor liver transplantation
Study NCT04768361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation without Mindfulness
Description: Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change.
Study NCT04768361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation with Mindfulness
Description: Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change.
Study NCT01934829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea-based cream
Description: urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator.
Study NCT00588965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + trastuzumab
Study NCT00588965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol LA
Description: Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
Study NCT04490148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT01008137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (ANFLU)
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Study NCT00567554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + lapatinib
Study NCT03254810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN060
Description: a single subcutaneous 0.57 mg/kg dose of SYN060
Study NCT03254810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab North American source
Description: a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
Study NCT03254810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab European source
Description: a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source